A new intranasal formulation of 5-MeO-DMT, called BPL-003, was tested in 44 healthy people who had never used psychedelics. Doses up to 12 mg were well tolerated, with no serious side effects; common mild effects included nasal discomfort, nausea, headache, and vomiting. The drug was absorbed quickly, reaching peak levels in about 8–10 minutes, and cleared from the body in under 27 minutes. Higher doses produced stronger subjective drug intensity and mystical experiences, with 60% of participants reporting a 'complete mystical experience' at 10 and 12 mg. The rapid onset and short duration suggest potential for treating conditions like depression.
A single 10 mg intranasal dose of the psychedelic drug BPL-003 (a formulation of 5-MeO-DMT) combined with cognitive behavioral therapy was safe and tolerable in people with moderate-to-severe alcohol use disorder. Over 12 weeks, the average percentage of abstinent days increased from 33.2% at baseline to 80.8%, and heavy drinking days dropped from 56.2% to 13.2%. Half of the 12 participants who completed the study were continuously abstinent, a quarter had meaningful reductions in drinking, and a quarter showed little change. Measures of craving, well-being, and quality of life also improved. The findings support larger controlled trials.
Nasal administration of tryptamine psychedelics significantly elevates mood in 70% of participants, based on a sample size of 150 individuals. This method enhances the effects on consciousness and psychological well-being, indicating strong potential in pharmacology and psychiatry. The study highlights how these substances influence neurotransmitter receptors, leading to altered states of awareness. With implications for forensic toxicology and drug analysis, findings suggest that psychedelics may offer new avenues for therapeutic applications in mental health.
A proof-of-concept trial tested intranasal 5-MeO-DMT combined with an SSRI in people with treatment-resistant depression. The treatment was generally well tolerated and showed preliminary signals of antidepressant effects, though the small, uncontrolled design limits conclusions.
A single dose of BPL-003, a psychedelic drug given as a nasal spray, was safe in people with treatment-resistant depression. Depression scores dropped quickly and stayed lower for 12 weeks, suggesting the drug may help this hard-to-treat condition. Larger controlled trials are needed.